Please assess the completion status of the following clinical trial:

Trial Title: Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~-INCLUSION:~18 years of age or older Have received prior chemotherapy for histologically proven advanced non-small cell lung cancer, up to 3 prior treatments Tumors display high ISG15 (ISG15H) at screening Life expectancy of at least 12 weeks ECOG/Zubrod performance status of 0-2 Provide informed consent permission to participate~Adequate bone marrow function as follows:~1. Absolute neutrophil count of greater than or equal to 1,500 or cells/mm3, and 2) Platelet count greater than or equal to 100,000/mm3 and 3) Absence of a regular red blood cell transfusion requirement~Adequate hepatic function with:~1. Total bilirubin less than or equal to 4.0 mg/dl, and~2. SGOT or SGPT less than or equal to four times ULN~Adequate renal function as defined by:~1) Serum creatinine less than or equal to 1.5 x ULN~Exclusion Criteria:~Symptomatic brain metastases~Pregnant women or nursing mothers~Patients of child bearing potential must use adequate contraception.~May not be receiving other concurrent chemotherapy or radiation therapy~Severe medical problems such as uncontrolled diabetes mellitus or cardiovascular disease or active infections~Previous hypersensitivity reaction to camptothecins

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Irinotecan (Type: EXPERIMENTAL): The starting dose of irinotecan for the study is 180 mg/m2, given intravenously every 14 days. Each 14 day period will constitute one cycle of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).